Insulin-like growth factor-I (IGF-I) is a nutritionally dependent bone trophic hormone which stimulates osteoblast function and collagen synthesis in vivo and in vitro. We hypothesized that in the fasting state, IGF-I levels would decline significantly and would establish a model in which we could investigate the effects of IGF-I administration on bone turnover. We therefore studied 14 normal women ages [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] 24±4 [SD] years) during a complete 10-d fast. After 4 d of fasting, subjects were randomized to receive rhIGF-I or placebo subcutaneously twice a day for 6 d. Bone turnover was assessed using specific markers of formation (osteocalcin and type I procollagen carboxyl-terminal propeptide [PICP]) and resorption (pyridinoline, deoxypyridinoline, type I collagen crosslinked N-telopeptide [N-telopeptide] and hydroxyproline). Serum levels of PICP and osteocalcin decreased from 143±52 to 60±28 ng/ml (P = 0.001) and from 7.6±5.4 to 4.2±3.1 ng/ml (P = 0.001) respectively with 4 d of fasting. Urinary excretion of pyridinoline and deoxypyridinoline decreased from 96±63 to 47±38 nmol/mmol creatinine (P < 0.05) and from 28±17 to 14±11 nmol/mmol creatinine (P < 0.05) respectively. Mean IGF-I levels decreased from 310±81 to 186±78 ng/ ml (P = 0.001).
Introduction
Insulin-like growth factor-I (IGF-I) is a nutritionally dependent bone trophic hormone which stimulates osteoblast function and collagen synthesis in vivo and in vitro. We hypothesized that in the fasting state, IGF-I levels would decline significantly and would establish a model in which we could investigate the effects of IGF-I administration on bone turnover. We therefore studied 14 normal women ages 19-33 (mean, 24±4 [SD] years) during a complete 10-d fast. After 4 d of fasting, subjects were randomized to receive rhIGF-I or placebo subcutaneously twice a day for 6 d. Bone turnover was assessed using specific markers of formation (osteocalcin and type I procollagen carboxyl-terminal propeptide [PICP] ) and resorption (pyridinoline, deoxypyridinoline, type I collagen crosslinked N-telopeptide [N-telopeptide] and hydroxyproline). Serum levels of PICP and osteocalcin decreased from 143±52 to 60±28 ng/ml (P = 0.001) and from 7.6±5.4 to 4.2±3.1 ng/ml (P = 0.001) respectively with 4 d of fasting. Urinary excretion of pyridinoline and deoxypyridinoline decreased from 96±63 to 47±38 nmol/mmol creatinine (P < 0.05) and from 28±17 to 14±11 nmol/mmol creatinine (P < 0.05) respectively. Mean IGF-I levels decreased from 310±81 to 186±78 ng/ ml (P = 0.001).
In the second part of the experimental protocol, serum osteocalcin and PICP levels increased 5-and 3-fold, respectively with rhIGF-I administration and were significantly elevated compared with the placebo group at the end of treatment (20.9±17.3 vs. 5 .9±6.4 ng/ml for osteocalcin [P < 0.05] and 188±45 vs. 110±37 ng/ml for PICP [P < 0.05]). In contrast, all four markers of bone resorption, including urinary pyridinoline, deoxypyridinoline, N-telopeptide and hydroxyproline were unchanged with rhIGF-I administration. This report is the first to demonstrate that bone turnover falls rapidly with acute caloric deprivation in normal women. RhIGF-I administration uncouples bone formation in this setting by significantly increasing bone formation, but not resorption. These data suggest a novel use of rhIGF-I to selectively stimulate bone formation in states of undernutrition and low bone turnover. (J. Clin. Invest. 1995. 96:900-906.) Key words: insulin-like growth factor I * bone turnover * fasting -nutrition * osteocalcin Insulin-like growth factor-I (IGF-I) is a critical endocrine factor in the physiological regulation of bone formation with potent effects on bone growth and remodeling. IGF-I acts through specific receptors on cells of osteoblast lineage to stimulate collagen synthesis (1) (2) (3) (4) and increase proliferation and differentiation of osteoblast precursor cells (5-7). IGF-I also functions as a paracrine factor in the local regulation of bone metabolism. Osteoblast transcription of IGF-I increases in response to stimulation by parathyroid hormone (PTH), growth hormone (GH)' and estrogen (8) (9) (10) (11) (12) . In turn, locally produced IGF-I may act to oppose the effects of PTH on osteoblasts (13, 14) .
The regulation of IGF-I is nutritionally dependent and circulating levels of IGF-I decline after acute fasting due to acquired GH resistance and increase with nutritional repletion (15) (16) (17) (18) . In severe chronic undernutrition, IGF-I concentrations decrease in association with low bone turnover and significant bone loss (19) (20) (21) (22) (23) . Similarly, bone turnover is diminished in other pathologic states in which IGF-I levels are deficient because of an inherited resistance to the action of GH or in association with decreased GH secretion (24) (25) (26) (27) (28) . These data suggest that IGF-I is an important modulator of normal bone metabolism and that a deficiency of IGF-I at systemic and/or tissue levels may contribute to abnormal bone metabolism in undernutrition. Recent experimental data demonstrate that recombinant human IGF-I (rhIGF-I) increases bone turnover in menopausal women (29) . However, the effects of rhIGF-I on bone turnoverin undernutrition and other pathologic conditions of low bone turnover have not been investigated.
We hypothesized that in the fasting state, IGF-I levels would decline significantly and would establish a model in which we could investigate the acute effects of IGF-I administration on bone turnover. Subjects were fasted for four days before randomization to treatment with rhIGF-I or placebo. Bone turnover was assessed at baseline and then again before and after treatment with rhIGF-I. Glomerular filtration rate (GFR) and fractional tubular reabsorption of calcium were also determined to assess renal handling of calcium during rhIGF-I therapy. Our findings demonstrate: (a) a significant decrease in indices of both bone formation and resorption during short-term fasting and (b) rhIGF-I administration uncouples bone formation and is a potent and selective osteoblast stimulator in states of acute undernutrition.
Methods

Experimental subjects
We studied 14 women with a mean age of 24±4 yr, range 19-33 yr. All patients gave written consent as approved by the Experimental endpoints. Serum electrolytes, calcium, phosphorus, IGF-I and insulin-like growth factor binding protein-3 (IGFBP-3) levels were measured at baseline (day 1) and daily on days [5] [6] [7] [8] [9] [10] [11] . Serum ionized calcium levels were available on days 5, 8, and 11. Serum osteocalcin, PICP, PTH, 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D levels were measured at baseline and days 5, 8, and 11. Insulin levels were measured on days 8 and 11. 24 h urine measurements for calcium, pyridinoline and deoxypyridinoline were made from 0800 to 0800 h on days 1-2, 4-5, 7-8, and 10-11. To further assess bone resorption during rhIGF-I administration, hydroxyproline and N-telopeptide levels were measured in urine samples collected on days 5, 8, and 11 of the study. Glomerular filtration rate (GFR), calcium filtration and fractional tubular reabsorption of calcium were calculated on days 5, 8, and 11 to determine the effects of rhIGF-I on renal calcium handling (see Appendix) (31) . Weight was measured daily and percent ideal body weight (%IBW) was calculated at baseline and days 5 and 11. Laboratory methods Serum total and ionized calcium, phosphorus, electrolytes, PTH, 25 hydroxyvitamin D, 1,25 dihydroxyvitarmin D and insulin levels were measured using published methods (32). Serum IGF-I was measured after an acid-alcohol extraction using a RIA kit with an intra-assay coefficient of variation 2.4-3.0% (Corning Nichols Institute). PICP was measured using a RIA kit with an intra-assay coefficient of variation of 2.1-3.2% (Incstar, Stillwater, MN). Osteocalcin was measured using a RIA kit with an intra-assay coefficient of variation of 5.7-8.1% (Corning Nichols Institute). Urinary excretion of pyridinoline and deoxypyridinoline were measured according to the methods of Uebelhart et al. and modified by Corning Nichols Institute (33) . Urinary excretion of N-telopeptide was measured by ELISA with a coefficient of variation Table I .
Statistical methods
The effects of rhIGF-I administration on experimental endpoints were determined using a mixed model analysis of variance (ANOVA). The random effects were subjects and time X subjects and the fixed effects were treatment, time, and time X treatment. The effect of treatment on each end point was measured by the time X treatment effect with the time X subject effect as an error term. Treatment groups were also compared by the Mann-Whitney test. To determine the effects of acute fasting, the changes in study endpoints from baseline (day 1) to day 5 (before the initiation of rhIGF-I) were compared in all subjects using the Wilcoxon Signed-Rank test. Unless noted otherwise, results are expressed as mean±SD.
Results
Baseline clinical data Baseline clinical and biochemical data for the entire study group are shown in Table I . At baseline, serum IGF-I, IGFBP-3, and markers of bone turnover, calcium metabolism and weight did not differ significantly in the rhIGF-I and placebo groups.
Part L Acute fasting Metabolic. Clinical and biochemical responses to 4 d of acute fasting are shown in Table I . Mean weight loss was 4.1±0.7 kg and represented a 7% decrease in IBW (P = 0.001). Serum IGF-I levels decreased by 40% (P = 0.001), but serum IGFBP-3 levels did not change significantly with fasting (Table I decreased significantly after 4 days of fasting (Fig. 2) . Serum levels of osteocalcin and PICP fell by 45% and 58% respectively (P = 0.001 for each variable, Table I ). Urinary excretion of pyridinoline and deoxypyridinoline also decreased significantly with fasting (Table I) . Serum calcium levels increased and PTH levels decreased significantly in association with an increase in urinary calcium levels (Table I) . Serum levels of 25-hydroxyvitamin D increased significantly with fasting and a single multivitamin per day, but levels of 1,25-dihydroxyvitamin D did not change significantly with acute fasting (Table I) .
Part II. Response to rhIGF-I administration Metabolic. Serum IGF-I levels peaked on the first day after treatment was begun in subjects receiving rhIGF-I and remained significantly elevated compared to the placebo group throughout the treatment period (Fig. 1) ,. IGFBP-3 levels were significantly decreased in women receiving rhIGF-I compared with placebo at the conclusion of the study (Fig. 1) . Despite the infusion of glucose, insulin levels were suppressed in both groups and were not significantly different (Table II) . Percent ideal body weight was also not significantly different in subjects receiving rhIGF-I compared with placebo. Serum bicarbonate levels normalized in both groups by day 8 of the protocol and were not significantly different in a comparison of subjects receiving rhIGF-I vs. placebo. Bone turnover. The rate of change of osteocalcin (P < 0.05) and PICP (P < 0.001) was significantly greater in the subjects who received rhIGF-I compared with the placebo group using a mixed model analysis of variance. In addition, serum osteocalcin and PICP levels were significantly higher in the rhIGF-I group compared to the placebo group at the conclusion of the study (Table II, Fig. 2 ). Urinary excretion of pyridinoline, deoxypyridinoline, N-telopeptide and hydroxyproline did not change significantly in either group (Table H, Fig. 2) .
The rate of change in ionized calcium, phosphorus, and PTH levels as well as urinary calcium excretion did not differ with respect to treatment by ANOVA (Table H) . Comparison between the treatment groups by the Mann-Whitney test on the final day of the study demonstrated that ionized calcium levels and urinary calcium excretion were higher in the rhIGF-I-treated group compared to the placebo group (P < 0.05), although both were decreased from baseline. In contrast, serum PTH levels were lower in the rhIGF-I-treated group (P < 0.05). Serum calcium levels and 25-hydroxyvitamin D levels decreased significantly in the rhIGF-I treated patients compared to placebo (P < 0.05), but the rate of change in 1,25-dihydroxyvitamin D levels was not different between the treatment groups (Table II) . The rate of change in GFR was significantly greater in subjects receiving rhIGF-I compared with placebo (P < 0.05) and mean GFR was significantly greater in the rhIGF-I vs. placebo treated group at the conclusion of the study [115±20 vs. 88±17 ml/minute (P < 0.05)] (Table II) . The change in GFR remained significant when corrected for weight. Calcium filtration increased in parallel with GFR in both groups (Table HI) . However, fractional tubular reabsorption of calcium was decreased in the rhIGF-I-treated patients compared with controls at the conclusion of the study [98.54±0.83 vs. 99.18±0.29% (P = 0.07) (Table II) .
Side effects. No significant side effects attributable to rhIGF-I administration occurred. Serum glucose levels were maintained above 60 mg/dl in all study subjects and no subjects experienced joint aches, fluid retention, parotid swelling or any other side effects of rhIGF-I administration. One woman in the placebo group and one in the rhIGF-I group dropped out on the fifth day, prior to randomization, because of an unwillingness to continue the fast. One additional woman in rhIGF-I group was discontinued from the protocol on day 10 when she developed an upper respiratory tract infection.
Discussion
Our results demonstrate that there is a profound decrease in biochemical indices of both bone formation and resorption during acute fasting and that rhIGF-I administration selectively stimulates bone formation in this setting. The One potential mechanism to explain the decline in bone turnover with short-term fasting is a decrease in systemic and/ or local bone IGF-I concentrations. Serum IGF-I concentrations are nutritionally dependent (15, 17) and decreased significantly after 4 d of fasting. Potent effects of IGF-I on osteoblast function and differentiation in vitro (2, 3, 5, 7) and bone protein synthesis and cancellous bone formation in animals and in humans have recently been demonstrated (29, 38, 39) . Our finding of decreased serum and urine markers of bone turnover is consistent with biochemical data from other pathologic conditions associated with deficient IGF-I concentrations (25, 28) . In addition, fasting-induced changes in IGF-I or its binding proteins may also affect bone turnover at the tissue level through local autocrine and paracrine actions (40) (41) (42) . Serum levels of IGFBP-3, a key determinant of free IGF-I tissue availability (43) , were constant while total IGF-I levels decreased during fasting. These data suggest that the percentage of free IGF-I available to bone tissue might have fallen to an even greater extent than reflected in total IGF-I levels. Fasting could also decrease bone turnover through an effect on a second IGF binding protein, IGFBP-1. Serum and local tissue levels of IGFBP-1 are known to increase with fasting as a result of decreased serum insulin levels (20, 44) . Recent animal data have demonstrated that increased IGFBP-1 levels during fasting inhibit collagen synthesis by affecting local binding of IGF-I binding to its receptor (36, 45) . Therefore, declining free IGF-I concentrations in bone tissue or activation of a local inhibitor to bone formation, such as IGFBP-1, may be one of the causes of the dramatic decrease in bone metabolism observed with fasting.
Additional mechanisms impacting on the fall in bone turnover with fasting include changes in serum PTH levels and acid base status. Serum and urinary calcium levels increased after 4 d of fasting in association with decreased PTH levels. The likeliest explanation for the decline in serum PTH levels was the increase in serum calcium levels. One potential mechanism suggested by studies in experimental animals to explain the increase in serum calcium is a direct effect of acidosis to demineralize bone (46) . Recent studies in postmenopausal women have demonstrated that acidosis might have a PTH-independent effect to alter bone metabolism (47) .
A critical observation in this study is the effect of IGF-I administration to increase bone formation and uncouple bone formation and resorption in acute fasting. Serum osteocalcin levels increased fivefold and PICP levels increased threefold during rhIGF-I administration, demonstrating the significant effect of rhIGF-I to increase bone formation in this experimental model. In contrast, sensitive markers of osteoclast activation and collagen degradation did not increase with rhIGF-I administration, consistent with the known effect of rhIGF-I to decrease collagen degradation in vitro (8) . Serum ionized calcium levels and urinary calcium excretion decreased in both treatment groups and did not differ by analysis of variance. In addition, (52, 53) . Estrogen deficiency was not present in our young female population and this may help to explain why rhIGF-I administration did not effect bone resorption. Treatment of bone cells with IGF-I in vitro increases production of interleukin-6 (IL-6), a cytokine which is known to stimulate osteoclast formation and bone resorption (49) . However, estrogen inhibits IL-6 expression in bone marrow-derived stromal cell cultures and may also act in vivo to modulate the effects of systemically administered rhIGF-I on cytokine production and bone resorption (54) . Furthermore, the model of acute fasting to alter endogenous IGF-I levels in our population is significantly different from the nutritionally replete population previously studied. A final explanation for our findings is that an effect on bone resorption may lag behind the immediate effects of rhIGF-I on bone formation in the fasting state. This study demonstrates that bone turnover falls rapidly during short-term fasting in normal women and that administration of rhIGF-I acts to selectively stimulate bone formation in this setting. Although further studies are needed to fully elucidate the mechanisms by which bone turnover responds to acute changes in nutritional status, we have demonstrated the potent effects of IGF-I to uncouple bone formation and resorption in women undergoing short-term fasting. These data suggest that rhIGF-I administration should be investigated as a novel therapy to selectively increase bone formation and bone mass in conditions of chronic undernutrition such as anorexia nervosa, or, low bone turnover.
